7,718.60

-29.11

-0.38%

53,414.25

-271.86

-0.51%

26,506.99

-77.11

-0.29%

2,975.65

+7.38

+0.25%

14.53

+0.21

+1.47%

4,476.60

-63.30

-1.39%

79,625.98

-1,559.30

-1.92%

Crude Oil Oct 26

91.48

+0.18

+0.20%

NasdaqGM - Delayed Quote USD

Fate Therapeutics, Inc. (FATE)

2.4800 +0.0600 (+2.48%)

At close: September 4 at 4:00:01 PM EDT

2.4493 -0.0307 (-1.24%)

After hours: September 4 at 7:30:03 PM EDT

Trade FATE on Coinbase

Loading Chart for FATE

Chart Range Bar

Interval:

In partnership with ChartIQ

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

ALLO

IPSC

NKTX

CRBU

IOVA

ATRA

CCCC

HRTX

AUTL

KYNB

Mobilize your Website

View Site in Mobile | Classic

Share by: